e-Article
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Document Type
Article
Source
In: The Lancet Diabetes and Endocrinology . (The Lancet Diabetes and Endocrinology, March 2024, 12(3):162-173)
Subject
Language
English
ISSN
22138595
22138587
22138587